The New Jersey Board of Medical Examiners has proposed to amend regulations under NJAC 13:35-7 to require practitioners to identify in advance psychological co-morbidities that affect prescribing and overall treatment decisions and assess whether continued opioid therapy is working to address a patient’s treatment needs. The rule also would address treatment planning, medical records, and management of chronic pain.

For more information, please contact NACDS’ Ben Pearlman at 617-515-2603.

The Board of Pharmacy has finalized three regulations dealing with patient counseling documentation requirements, increased out of state permit fees, and removal of waiting period to retake pharmacist exams. 

For more information, please contact NACDS’ Ben Pearlman at 617-515-2603.

The Board of Pharmacy has adopted regulations on opioid warning labels. These regulations are effective January 3, 2022.

For more information, please contact NACDS’ Ben Pearlman at 617-515-2603.

Governor Phil Murphy (D) signed into law A-1259 / S-249  which requires pharmacy benefits managers providing services within the Medicaid program to disclose certain information to the Department of Human Services. Program to require the pharmacy benefits manager to disclose to the department: (1) all sources and amounts of income, payments, and financial benefits received by the pharmacy benefits manager in relation to the provision and administration of pharmacy benefits management services on behalf of the managed care organization, including, but not limited to, any pricing discounts, rebates of any kind, inflationary payments, credits, clawbacks, fees, grants, chargebacks, reimbursements, or other benefits; (2) all ingredient costs and dispensing fees or similar payments made by the pharmacy benefits manager to any pharmacy in connection with the contract or other arrangement; and (3) the pharmacy benefits manager’s payment model for administrative fees.  Information reported by pharmacy benefits managers under the bill will be confidential and will not be subject to disclosure under the “Open Public Records Act.” 

 This law goes into effect immediately. 

For more information, please contact NACDS’ Ben Pearlman at 617-515-2603.

The New Jersey Board of Pharmacy is proposing to adopt regulations under NJAC 13:39-1 to require pharmacy permit holders and registered pharmacists-in-charge to implement a continuous quality improvement program to prevent prescription errors.

For more information, please contact NACDS’ Ben Pearlman at 617-515-2603.

The New Jersey Board of Pharmacy proposed to adopt regulations under NJAC 13:39-1 to require pharmacy permit holders and registered pharmacists-in-charge to implement a continuous quality improvement program to prevent prescription errors.

For more information, please contact NACDS’ Ben Pearlman at 617-515-2603.

Governor Phil Murphy (D) recently signed into law two opioid proposals. The first is AB 5595 which requires the Director of the Division of Consumer Affairs to include opioid antidotes on the list of prescription drugs provided to pharmacies and then requires pharmacies to include opioid antidotes on its prescription drug retail price list available to customers. Governor Murphy also signed into law AB 5703 which requires coverage for an opioid antidote without imposing prior authorization requirements.

For more information, please contact NACDS’ Ben Pearlman at 617-515-2603.

Governor Phil Murphy (D) signed into law A5820/S3866 ending the COVID 19 Public Health Emergency that has been in place since March 9, 2020. Many of the executive orders issued under the Public Health Emergency will expire by July 4, 2021.  Only Executive Orders that govern vaccinations and testing will remain in effect until January 11, 2022.

For more information, please contact NACDS’ Ben Pearlman at 617-515-2603.